InVivo Therapeutics Holdings Corp. (OTC:NVIV) burned through nearly one-fourth of its cash during the first quarter as it adjusted to life as a publicly traded firm.
The Cambridge, Mass.-based startup, which is developing an implantable treatment for acute spinal cord injuries, said it had $6.84 million in cash and current assets as of March 31, down $2.1 million from $8.96 million as of Dec. 31, 2010.